

PROGENICS PHARMACEUTICALS INC

Form 8-K

March 13, 2014

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 13, 2014

Progenics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-23143

13-3379479

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS  
Employer  
Identification  
No.)

777 Old Saw Mill River Road,  
Tarrytown, New York

10591

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (914) 789-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 2.02. Results of Operations and Financial Condition.

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced its operational results for the fourth quarter and full-year 2013. A copy of its press release is included in this Report as Exhibit 99.1.

The information furnished pursuant to this Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the U.S. Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Exchange Act or the U.S. Securities Act of 1933. We undertake no duty or obligation to publicly update or revise the information so furnished.

Item 8.01. Other Events.

The company also announced in its release that it is initiating clinical development of MIP-1095, a prostate-specific membrane antigen (PSMA)-targeted small molecule radiopharmaceutical product candidate for the treatment of prostate cancer.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release dated March 13, 2014.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ ANGELO W. LOVALLO, JR.

Angelo W. Lovallo, Jr.

Vice President, Finance & Treasurer

(Principal Financial and Accounting Officer)

Date: March 13, 2014